Fuller & Thaler Asset Management Inc. Invests $445,000 in Evolent Health, Inc $EVH

Fuller & Thaler Asset Management Inc. purchased a new position in shares of Evolent Health, Inc (NYSE:EVH) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 46,940 shares of the technology company’s stock, valued at approximately $445,000.

A number of other hedge funds have also made changes to their positions in EVH. Banque Cantonale Vaudoise acquired a new stake in shares of Evolent Health during the first quarter worth approximately $25,000. US Bancorp DE grew its position in shares of Evolent Health by 291.0% during the first quarter. US Bancorp DE now owns 5,153 shares of the technology company’s stock worth $49,000 after buying an additional 3,835 shares in the last quarter. Signaturefd LLC grew its position in shares of Evolent Health by 400.6% during the first quarter. Signaturefd LLC now owns 7,043 shares of the technology company’s stock worth $67,000 after buying an additional 5,636 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Evolent Health by 5,036.4% during the first quarter. GAMMA Investing LLC now owns 9,451 shares of the technology company’s stock worth $90,000 after buying an additional 9,267 shares in the last quarter. Finally, State of Wyoming acquired a new position in Evolent Health in the fourth quarter worth $95,000.

Evolent Health Stock Performance

Shares of EVH opened at $8.7120 on Friday. Evolent Health, Inc has a 1 year low of $7.06 and a 1 year high of $33.63. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -5.41 and a beta of 0.82. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The firm has a fifty day moving average of $10.04 and a 200-day moving average of $9.56.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.20). Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The firm had revenue of $444.33 million for the quarter, compared to analyst estimates of $459.43 million. During the same period last year, the firm posted $0.30 EPS. The business’s revenue was down 31.3% compared to the same quarter last year. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities analysts anticipate that Evolent Health, Inc will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Truist Financial lifted their price objective on shares of Evolent Health from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Evolent Health in a report on Tuesday, May 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. Finally, UBS Group lifted their price objective on shares of Evolent Health from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Evolent Health presently has a consensus rating of “Buy” and a consensus price target of $17.93.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.